Realization and dissemination of activity standards for medically important alpha-emitting radionuclides

Bergeron, Denis E.; Kossert, Karsten; Collins, S.M.; Fenwick, Andrew

doi:10.1016/j.apradiso.2022.110161

Cited by 3 publications

(1 citation statement)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The sensitivity of the detectors is of significant importance since the activity in the samples is limited due to health physics regulations. Due to the challenges of QC analysis, cross-validation of the different methods is recommended to ensure the quality (Bergeron et al 2022 ).…”

Section: Quality Control (Qc) and Detectionmentioning

confidence: 99%

Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives

Hooijman,

Radchenko,

Ling

et al. 2024

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

Background In the past years, there has been a notable increase in interest regarding targeted alpha therapy using Ac-225, driven by the observed promising clinical anti-tumor effects. As the production and technology has advanced, the availability of Ac-225 is expected to increase in the near future, making the treatment available to patients worldwide. Main body Ac-225 can be labelled to different biological vectors, whereby the success of developing a radiopharmaceutical depends heavily on the labelling conditions, purity of the radionuclide source, chelator, and type of quenchers used to avoid radiolysis. Multiple (methodological) challenges need to be overcome when working with Ac-225; as alpha-emission detection is time consuming and highly geometry dependent, a gamma co-emission is used, but has to be in equilibrium with the mother-nuclide. Because of the high impact of alpha emitters in vivo it is highly recommended to cross-calibrate the Ac-225 measurements for used quality control (QC) techniques (radio-TLC, HPLC, HP-Ge detector, and gamma counter). More strict health physics regulations apply, as Ac-225 has a high toxicity, thereby limiting practical handling and quantities used for QC analysis. Conclusion This overview focuses specifically on the practical and methodological challenges when working with Ac-225 labelled radiopharmaceuticals, and underlines the required infrastructure and (detection) methods for the (pre-)clinical application.

show abstract

Section: Quality Control (Qc) and Detectionmentioning

confidence: 99%